

Details of Q1 FY26 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) advises that it will release its Q1 FY26 Quarterly Activities Report, Appendix 4C and Quarterly Investor Presentation on Tuesday, 28 October 2025. The Company will also host a Quarterly Investor Webinar on Tuesday, 28 October 2025. The details of the Quarterly Investor Webinar are below.

Quarterly Investor Webinar

Presented by: CEO, Dr Luke Reid

Date & Time: 11:00am AEST (Brisbane) / 12:00pm (midday) AEDT (Sydney/Melbourne) on Tuesday, 28 October 2025

Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via Microba’s Investor Hub at the following link: <https://ir.microba.com/webinars/0y52Ge-q1-fy26-quarterly-investor-webinar>

Submit Your Questions

We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the ‘Ask a question’ section of Microba’s interactive investor platform by following this link: <https://ir.microba.com/webinars/0y52Ge-q1-fy26-quarterly-investor-webinar>

Stay Informed

To receive notifications when Microba releases its Quarterly Report, Investor Presentations, and other key announcements, sign up to the Microba Investor Hub:

1. Visit <https://ir.microba.com/welcome>
2. Follow the prompts to sign up for an account.
3. Complete your account profile.

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

luke.reid@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA’S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621